About

Mellitor Ltd. is developing an implanted glucose sensor for the continuous monitoring of glucose in diabetics. Mellitor’s sensor is designed to be implanted for an extended period (similar to a pacemaker) in diabetic patients, and give a real-time, highly accurate, measurement of the glucose level in the interstitial fluid. The unique implantable approach of the company, and its patented technology, resolves the problems that have prevented other companies from providing sufficiently accurate continuous glucose monitoring solutions to this market. We close the loop!

Utilising the existing Mellitor core technology the company is in process of completing its development of a new type of HPLC polarimeter..

DEVELOPMENT STATUS

Mellitor has conducted a preliminary study in its laboratory, using its prototype sensor to measure glucose concentration in spiked diluted bovine serum. The measurements were compared to the readings of a commercial glucose meter. The company conducted ~350 measurements on a range from 50 to 400 mg/dl. The sensor showed excellent linearity over the full range of the measuremnt. All the measurements were in the clinically accurate"A" area as shown in the industry standard Clarke Error Grid. The current resolution of the device is -/+ 1 mg/dL, which corresponds to -/+ 1% of physiological glucose concentration.

TECHNOLOGY & INTELLECTUAL PROPERTY

Mellitor has applied for four patents protecting the intellectual property of the very key aspects of its technology.

MARKET POTENTIAL

The World Health Organization (WHO) estimates that more than 180 million people worldwide have diabetes. This number is likely to more than double by 2030. In 2005, an estimated 1.1 million people died from diabetes. WHO projects that diabetes-related death will increase by more than 50% in the next 10 years without urgent action. Most notably, diabetes-related deaths are projected to increase by over 80% in upper-middle income countries between 2006 and 2015.

COMPETITION

A number of companies are supplying glucose biosensors for continuous monitoring. The life spans of these sensors are only several days and they need to be calibrated between 1 and 3 times a day. The FDA also requires the patient to confirm, before insulin treatment, the results received from these biosensors to a standard glucometer due to the inaccuracy of these devices. Mellitor believes that its product provides an effective solution for all these problems.